Reversion of multidrug resistance in HL-60/VCR cells by down-regulation of bcl-2 with bcl-2 siRNA.
- Author:
Ying PIAO
1
;
Xie-Qun CHEN
;
Li-Mei LIU
;
Liu HONG
;
Jing-Hua LIU
;
Fan ZHOU
;
Yan-Qin LIU
Author Information
1. Department of Hematology, General Hospital of Shenyang Millitary Area, Shenyang 110016, China. bakyung@fmmu.edu.cn
- Publication Type:Journal Article
- MeSH:
Blotting, Western;
DNA-Binding Proteins;
metabolism;
Down-Regulation;
genetics;
Drug Resistance, Multiple;
genetics;
Drug Resistance, Neoplasm;
genetics;
HL-60 Cells;
Humans;
Proto-Oncogene Proteins c-bcl-2;
genetics;
RNA, Small Interfering;
genetics;
Transfection;
Vincristine;
pharmacology;
bcl-2-Associated X Protein;
metabolism
- From:
Journal of Experimental Hematology
2005;13(6):1010-1013
- CountryChina
- Language:Chinese
-
Abstract:
To evaluate the feasibility of gene therapy using bcl-2 as target in multiple drug resistance of leukemia, the small interfering RNA eukaryotic expression vector specific to human bcl-2 gene was constructed by gene recombination, then transfected into HL-60/VCR cells. Stable transfectants were obtained by G418 screening. The growth curve and drug sensitivity were detected by using MTT. The expression of Bax and ZNRD1 was analyzed by Western blot. The results showed that mU6pro-bcl-2 siRNA was successfully constructed and transfected into HL-60/VCR cells. The IC(50) of transfected cells to vincristine and adriamycin was significantly reduced as compared with that of the control. The expression of ZNRD1 in transfected cells was decreased as compared with that of the control, while Bax not. It is concluded that the bcl-2 siRNA restores the sensitivity of HL-60/VCR cells to conventional chemotherapeutic agents to a certain degree.
